ABCL (AbCellera Bio) Market Value to Book Value Ratio
AbCellera Biologics (ABCL) develops immunological drugs, however, vulnerability to supply chain disruptions and trade barriers is constraining growth, which is reflected in the asset's price chart at 4.40. The company's financial stability depends on antibody payments and the success of its partners. The business is currently shifting its strategy, aiming to independently bring drugs to market instead of simply transferring rights to pharma behemoths.
%3A%20Market%20Capitalization%20to%20Net%20Assets&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_ABCL_-_AbCellera-Biologics_-_Market-Capitalization-to-Net-Assets "ABCL AbCellera Biologics Inc. Market Capitalization to Book Value Ratio (07/04/2022 - 10/28/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for abcellera.com (ABCL)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:AbCellera Biologics Inc - ABCL
Amidst fierce competition with AI labs and CRO giants, the success of AbCellera Biologics (ABCL) depends on the market recognition of its intellectual assets. Analyzing the historical market cap to book value ratio allows for a comparison of current market value against tangible capital, revealing the degree of speculative overvaluation and the risk of a price collapse during a shift in the investment cycle.
Main competitors
argenx SE (ARGX) - Market Value to Book Value Ratio|BNTX (biontech.de) - Market Value to Book Value Ratio|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|BioCryst Corp (BCRX) - Market Cap to Net Assets Ratio|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com (DNTH)|Pharvaris (PHVS) - Market Cap to Net Assets Ratio|Market Value to Book Value Tourmaline Bio Inc (TRML)|Market Capitalization to Book Value Ratio PGEN|Pharming Corp - Market Capitalization to Book Value|NKTR: Market Value to Book Value Ratio|UPB: Market Cap to Net Assets Ratio|ZBIO (Zenas Biopharma) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|GOSS (Gossamer Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio KALV|Market Value to Book Value Ratio Septerna Inc SEPN|Capitalization to Book Value Ratio pieris.com (PVLA)|SVRA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rigel Pharma RIGL|AnaptysBio Corp - Market Capitalization to Book Value Ratio|ATXS - Market Capitalization to Book Value Ratio|enGene Holdings Inc. (ENGN) - Market Capitalization to Book Value Ratio|rapt.com (RAPT) - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio JBIO|Market Cap to Net Assets Ratio Aclaris Therapeutics Inc.|Kyverna - Market Capitalization to Book Value Ratio|Market-to-Book Ratio TLSA (Tiziana Life Sciences, Ltd.)|Market Value to Book Value Ratio Cabaletta Bio, Inc. CABA|ventyxbio.com - Market Value to Book Value Ratio|THTX - Market Value to Book Value Ratio|AVTX - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio ELDN|AGEN (Agenus, Inc) - Market-to-Book Ratio|CLYM - Market Value to Book Value Ratio|Market Value to Book Value zurabio.com|Market Capitalization to Book Value Ratio ATYR|Market Capitalization to Book Value Ratio adagene.com ADAG|Market Cap to Net Assets Ratio Ikena Oncology|Market Value to Book Value Shattuck Labs Inc STTK|EQ - Market Capitalization to Book Value Ratio|CNTB - Market Value to Book Value Ratio|immunic-therapeutics.com - Market Capitalization to Book Value Ratio|ATRA (Atara Bio) - Market Capitalization to Book Value|Market Value to Book Value Ratio IFRX (InflaRx NV)|Market-to-Book Ratio XFOR|Market Value to Book Value Ratio Adicet Bio (ACET)|Market Value to Book Value Ratio CELU (celularity.com)|INMB: Market Value to Book Value Ratio|Market-to-Book Ratio Barinthus Biotherapeutics PLC BRNS|Market Capitalization to Book Value Ratio KZR|SABS - Market Value to Equity Ratio|Akari Therapeutics - Market Capitalization to Book Value Ratio|Enlivex Therapeutics Ltd. (ENLV) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio QTTB|Market Cap to Net Assets Ratio GOVX|EDSA (Edesa) - Market Value to Book Value Ratio|Market Capitalization to Book Value iBio Corporation (IBIO)|Market Capitalization to Book Value Ratio CARM (Carisma Therapeutics Inc.)|Market Capitalization to Book Value Ratio xtlbio.com XTLB|BOLT - Market Capitalization to Book Value Ratio|HCWB - Market Value to Book Value Ratio|APVO (aptevotherapeutics.com) - Market Capitalization to Book Value Ratio|AIM (aimimmuno.com) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Aditxt Inc.|Market Value to Book Value Ratio GRI|XRTX - Market Value to Book Value Ratio|Market Capitalization to Net Assets Vyome Holdings Inc. (HIND)|Market Capitalization to Book Value Ratio Revelation Bio|Market Value to Book Value Indaptus Corp INDP|Scinai Immunotherapeutics - Market Capitalization to Book Value Ratio|CALI: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio affimed.com AFMD|ALLK (Allakos) - Market Value to Book Value|Market Value to Book Value Ratio HOOK|Market Cap to Net Assets Ratio IGM Bio|Market Capitalization to Book Value Ratio ITOS|Market Capitalization to Book Value Ratio oceanbiomedical.com OCEA|Market Cap to Net Assets Ratio TC BioPharm|Market Value to Book Value Third Harmonic Bio Inc. THRD